{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:56:14Z","timestamp":1793728574620,"version":"4.6.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) or relapsed\/refractory (R\/R) follicular lymphoma (FL). In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL\/SLL (n = 45) and FL (n = 36). Common adverse events (AEs) included upper respiratory tract infection (51%; n = 23), neutropenia (44%; n = 20), contusion (33%; n = 15), cough, diarrhea, or fatigue (27%; n = 12 each), and pyrexia (22%; n = 10) in CLL\/SLL patients and upper respiratory tract infection (39%; n = 14), contusion (28%; n = 10), fatigue (25%; n = 9), and cough (22%; n = 8) in FL patients. Neutropenia was the most common grade 3\/4 AE (CLL\/SLL, 31% [n = 14]; FL, 14% [n = 5]). Five patients required temporary dose reductions, and 5 discontinued the study drug because of AEs. Overall response rate (ORR) was 100% (n = 20) in treatment-na\u00efve CLL patients and 92% (n = 23) in R\/R CLL patients. ORR in 36 R\/R FL patients was 72% (n = 26), with 14 complete and 12 partial responses. Median follow-up was 29 months (range, 8-37) for CLL patients and 20 months (range, 2-37) for FL patients. Zanubrutinib and obinutuzumab combination therapy was generally well tolerated. This trial was registered at www.clinicaltrials.gov as #NCT02569476.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002183","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:36:22Z","timestamp":1601998582000},"page":"4802-4811","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma"],"prefix":"10.1182","volume":"4","author":[{"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, St Vincent\u2019s Hospital, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Haematology, St Vincent\u2019s Hospital, University of Melbourne, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nicol","sequence":"additional","affiliation":[{"name":"Brisbane Clinic for Lymphoma, Myeloma, and Leukaemia, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Badoux","sequence":"additional","affiliation":[{"name":"Department of Haematology, St George Hospital, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Rose","sequence":"additional","affiliation":[{"name":"University Hospital, Geelong, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Epworth Healthcare, Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Leahy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Perth Hospital, University of Western Australia, Perth, WA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2357-1781","authenticated-orcid":false,"given":"Richard","family":"Eek","sequence":"additional","affiliation":[{"name":"Border Medical Oncology, Albury, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wickham","sequence":"additional","affiliation":[{"name":"Ashford Cancer Centre Research, Adelaide Cancer Centre, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Patil","sequence":"additional","affiliation":[{"name":"Alfred Hospital and Monash University, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Huang","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Prathikanti","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Cohen","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Elstrom","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Reed","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Schneider","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"12","key":"2020100611361280600_B1","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma","volume":"136","author":"Bernard","year":"2015","journal-title":"Int J Cancer"},{"issue":"11","key":"2020100611361280600_B2","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2020100611361280600_B3","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton\u2019s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020100611361280600_B4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"17","key":"2020100611361280600_B5","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"issue":"23","key":"2020100611361280600_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial","volume":"126","author":"Tam","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020100611361280600_B7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"2020100611361280600_B8","article-title":"A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: the Aspen study [published online ahead of print 30 July 2020]","author":"Tam","journal-title":"Blood"},{"issue":"7","key":"2020100611361280600_B9","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.3324\/haematol.2015.140806","article-title":"Phase I study of single-agent CC-292, a highly selective Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory chronic lymphocytic leukemia","volume":"101","author":"Brown","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2020100611361280600_B10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2020100611361280600_B11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2020100611361280600_B12","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2020100611361280600_B13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2020100611361280600_B14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014;370(8):786]","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2020100611361280600_B15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"26","key":"2020100611361280600_B16","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2020100611361280600_B17","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020100611361280600_B18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"2020100611361280600_B19","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1080\/10428194.2018.1460474","article-title":"A drug-drug interaction study of ibrutinib with moderate\/strong CYP3A inhibitors in patients with B-cell malignancies","volume":"59","author":"de Jong","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020100611361280600_B20","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"2020100611361280600_B21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-019-04015-w","article-title":"Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton\u2019s tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects","volume":"85","author":"Mu","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020100611361280600_B22","first-page":"180","author":"Swerdlow","year":"2017","edition":"Revised 4th ed"},{"key":"2020100611361280600_B23","author":"National Cancer Institute"},{"key":"2020100611361280600_B24","article-title":"GAZYVA (obinutuzumab) injection, for intravenous use [prescribing information]","year":"2020"},{"issue":"23","key":"2020100611361280600_B25","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020100611361280600_B26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020100611361280600_B27","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020100611361280600_B28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: a European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"23","key":"2020100611361280600_B29","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"2020100611361280600_B30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"30","key":"2020100611361280600_B31","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020100611361280600_B32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/01.HS9.0000562920.26603.5b","article-title":"Pooled analysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies [abstract]","volume":"3","author":"Tam","year":"2019","journal-title":"HemaSphere"},{"issue":"1","key":"2020100611361280600_B33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"2020100611361280600_B34","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020100611361280600_B35","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [published correction appears in Blood Adv. 2018;2(23):3515]","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"2020100611361280600_B36","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ejh.13148","article-title":"The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)","volume":"101","author":"Chen","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"2020100611361280600_B37","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3324\/haematol.2018.212597","article-title":"Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels","volume":"105","author":"Velez Lujan","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2020100611361280600_B38","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"9747","key":"2020100611361280600_B39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"2020100611361280600_B40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"10232","key":"2020100611361280600_B41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"2020100611361280600_B42","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2020100611361280600_B43","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"2020100611361280600_B44","author":"Woyach"},{"key":"2020100611361280600_B45","author":"Tam","year":"2017"},{"issue":"23","key":"2020100611361280600_B46","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020100611361280600_B47","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"2020100611361280600_B48","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4802\/1760514\/advancesadv2020002183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4802\/1760514\/advancesadv2020002183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:36:41Z","timestamp":1601998601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/19\/4802\/464076\/Zanubrutinib-BGB3111-plus-obinutuzumab-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":48,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002183","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]}}}